CAMBRIDGE, Mass. — Montai Therapeutics, a biotechnology company using artificial intelligence to decode diverse and untapped chemistry for the development of breakthrough medicines targeting chronic diseases, has appointed Hans Hull as Chief Operations Officer.
“As Montai plans to enter the clinic in 2026 with our first program and scale our pipeline of high-value assets for major inflammatory diseases, we are integrating proven leaders to help us evolve our strategy, strengthen our organization, and create strategic partnerships,” said Margo Georgiadis, Co-founder and CEO of Montai and CEO-Partner at Flagship Pioneering. “This will enable us to fully capture the value of Montai’s transformative diverse chemistry and leading-edge AI to bring breakthrough solutions to patients. I am excited to partner with Hans in building a bold future for Montai given his strong track record of building high-performing organizations, corporate strategies, financing, and transformative strategic partnerships to unlock value creation.”
Hull brings more than two decades of experience in corporate development, legal, and operational leadership. He joins Montai from Pliant Therapeutics, where he served as Chief Business Officer. Previously, he was interim President and Chief Executive Officer at Avalanche Biotechnologies, a public gene therapy company, and CEO of Orthobond Corporation. During his career, Hull has led multiple strategic transactions, including a four-target, $500 million fibrosis collaboration with Novartis, an eight-product, $640 million collaboration with Regeneron Pharmaceuticals, and more than $700 million in public and private equity financing. Earlier in his career, he worked as an intellectual property attorney at Heller Ehrman LLP and as a life science consultant at ZS Associates. He holds an A.B. in Chemistry from Princeton University and a J.D. from the University of California, Berkeley.
“As an emerging biotech innovator leveraging the intersection of advanced AI and novel chemistry, Montai is in a unique position to discover next-generation oral therapies to treat chronic inflammatory diseases and far beyond,” said Hull. “My goal is to refine a strong operational network to enable the success of this highly integrated approach. I look forward to collaborating with Montai’s expert executive team, building on our successful partnership with Pfizer in oncology, and designing high-impact collaborations with future partners to bring new treatment options to patients.”
